Mingyu Liang, MB, PhD
Professor and Eminent Scholar; Director, Center of Systems Molecular Medicine
Postdoctoral Fellow, Nephrology, Mayo Clinic and Foundation, 2000
Postdoctoral Fellow, Physiology, Medical College of Wisconsin, 2002
MB - Medicine, Shanghai Medical University, 1994
Honors and Awards
2017: Distinguished Lectureship in Physiological Genomics Research, American Physiological Society
2015-present: Center Director, American Heart Association Strategically Focused Hypertension Research Center (including basic, clinical and population research)
2012: Henry Pickering Bowditch Award, American Physiological Society
2009: Outstanding Teacher of the Year, MCW Graduate School
2007-2015: Associate Editor, Physiological Genomics
1994: Outstanding Graduate, Shanghai Municipality
My laboratory's research interest is in understanding and integrating multiple aspects and components of physiology. In the context of hypertension and cardiovascular and kidney diseases, our current work focuses on three areas: regulatory RNA, cellular metabolism, and precision medicine and epigenomics. We have a diverse research platform that enables studies that integrate human research with animal and cell model research. We use a variety of approaches including genome-scale analysis, genetic engineering, molecular, biochemical and physiological measurements, and clinical study.
For a complete list of our laboratory’s publications since 2002, search PubMed for “Mingyu Liang”.
Research Area 1: Regulatory RNA
The general significance of microRNAs in the regulation of gene expression, cellular function, and disease development is now widely recognized. However, the specific role of many microRNAs, and other regulatory RNA such as long non-coding RNA, in physiological and disease processes remain unknown. Our laboratory investigates the role of microRNAs and other regulatory RNA in hypertension and cardiovascular and renal injury in humans and model systems.
Widlansky ME, Jensen DM, Wang J, Liu Y, Geurts AM, Kriegel AJ, Liu P, Ying R, Zhang G, Casati M, Chu C, Malik M, Branum A, Tanner MJ, Tyagi S, Usa K, Liang M. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol Med 2018; e8046.
Kriegel AJ, Baker MA, Liu Y, Liu P, Cowley AW Jr, Liang M. Endogenous microRNAs in human microvascular endothelial cells regulate mRNAs encoded by hypertension-related genes. Hypertension. 2015 Oct; 66(4): 793-9.
Mladinov D, Liu Y, Mattson DL, Liang M. MicroRNAs contribute to the maintenance of cell-type-specific physiological characteristics: miR-192 targets Na+/K+-ATPase β1. Nucleic Acids Res. 2013 Jan; 41(2): 1273-83.
Xu X, Kriegel AJ, Liu Y, Usa K, Mladinov D, Liu H, Fang Y, Ding X, Liang M. Delayed ischemic preconditioning contributes to renal protection by upregulation of miR-21. Kidney Int. 2012 Dec; 82(11): 1167-75.
Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr, Ferreri NR, Yeo NC, and Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010 Apr; 55(4):974-82.
Tian Z, Greene AS, Pietrusz JL, Matus IR, and Liang M. microRNA-target pairs in rat kidneys identified through microRNA microarray, proteomic, and bioinformatic analysis. Genome Res 2008 March; 18: 404-411.
Research Area 2 – Cellular metabolism
Our laboratory routinely combines exploratory approaches and hypothesis-driven approaches to discover novel disease mechanisms in humans and animal models. Recent discoveries that we are exploring in depth include novel roles of abnormalities in cellular metabolism in the development of hypertension and tissue injury.
Cheng Y, Song H, Pan X, Xue H, Wan Y, Wang T, Tian Z, Hou E, Lanza IR, Liu P, Liu Y, Laud PW, Usa K, He Y, Liang M. Urinary Metabolites Associated with Blood Pressure on a Low- or High-Sodium Diet. Theranostics 2018; 8(6):1468-1480.
Hou E, Sun N, Zhang F, Zhao C, Usa K, Liang M, Tian Z. Malate and Aspartate Increase L-arginine and Nitric Oxide and Attenuate Hypertension. Cell Rep. 2017 May; 19(8): 1631-1639.
Liang M. Hypertension as a mitochondrial and metabolic disease. Kidney Int. 2011 Jul; 80(1): 15-6.
Tian Z, Liu Y, Usa K, Mladinov D, Fang Y, Ding X, Greene AS, Cowley AW Jr, Liang M. Novel Role of Fumarate Metabolism in Dahl Salt-Sensitive Hypertension. Hypertension 2009 Aug; 54(2): 255-60.
Research Area 3 – Precision medicine and epigenomic
We collaborate with clinicians to develop innovative approaches to precision medicine for common cardiovascular and renal diseases with a particular focus on the incorporation of tissue functional genomic analysis. In conjunction with our work on functional genomics-based precision medicine, we study molecular regulatory networks, including epigenomic mechanisms, underlying physiology and disease.
Baker MA, Davis SJ, Liu P, Pan X, Williams AM, Iczkowski KA, Gallagher ST, Bishop K, Regner KR, Liu Y, Liang M. Tissue-Specific MicroRNA Expression Patterns in Four Types of Kidney Disease. J Am Soc Nephrol. 2017 Oct; 28(10): 2985-2992.
Touyz RM, Montezano AC, Rios F, Widlansky ME, Liang M. Redox Stress Defines the Small Artery Vasculopathy of Hypertension: How Do We Bridge the Bench-to-Bedside Gap? Circ Res. 2017 May; 120(11): 1721-1723.
Kotchen TA, Cowley AW Jr, Liang M. Ushering hypertension into the new era of precision medicine. JAMA 2016 Jan; 315(4): 343-4.
Liu Y, Liu P, Yang C, Cowley AW Jr, Liang M. Base-resolution maps of 5-methylcytosine and 5-hydroxymethylcytosine in Dahl S rats: effect of salt and genomic sequence. Hypertension. 2014 Apr; 63(4): 827-38.
(Zheng X, Chen M, Li X, Yang P, Zhao X, Ouyang Y, Yang Z, Liang M, Hou E, Tian Z.) Hypertens Res. 2019 Nov;42(11):1672-1682 PMID: 31235845 SCOPUS ID: 2-s2.0-85068127402 06/27/2019
(Xue H, Geurts AM, Usa K, Wang F, Lin Y, Phillips J, Henderson L, Baker MA, Tian Z, Liang M.) Hypertension. 2019 08;74(2):313-322 PMID: 31230549 PMCID: PMC6620137 SCOPUS ID: 2-s2.0-85069627359 06/25/2019
(Reimer M Jr, Pulakanti K, Shi L, Abel A, Liang M, Malarkannan S, Rao S.) BMC Dev Biol. 2019 07 08;19(1):16 PMID: 31286885 PMCID: PMC6615237 SCOPUS ID: 2-s2.0-85068878011 07/10/2019
(Liu Y, Liang M.) Kidney Int. 2019 Jul;96(1):10-12 PMID: 31229025 SCOPUS ID: 2-s2.0-85066848304 06/24/2019
(Kong Y, Lu Z, Liu P, Liu Y, Wang F, Liang EY, Hou FF, Liang M.) Compr Physiol. 2019 Jun 12;9(3):933-946 PMID: 31187897 SCOPUS ID: 2-s2.0-85067798712 06/13/2019
(Liang M.) Acad Med. 2019 03;94(3):300-301 PMID: 30817340 SCOPUS ID: 2-s2.0-85064812577 03/01/2019
(Baker MA, Wang F, Liu Y, Kriegel AJ, Geurts AM, Usa K, Xue H, Wang D, Kong Y, Liang M.) Hypertension. 2019 02;73(2):399-406 PMID: 30595117 PMCID: PMC6339564 SCOPUS ID: 2-s2.0-85059796489 01/01/2019
(Liu Y, Kriegel AJ, Liang M.) Methods Mol Biol. 2019;2018:177-194 PMID: 31228157 SCOPUS ID: 2-s2.0-85068180336 06/23/2019
(Wei Q, Sun H, Song S, Liu Y, Liu P, Livingston MJ, Wang J, Liang M, Mi QS, Huo Y, Nahman NS, Mei C, Dong Z.) J Clin Invest. 2018 12 03;128(12):5448-5464 PMID: 30325740 PMCID: PMC6264638 SCOPUS ID: 2-s2.0-85058349510 10/17/2018
(Liang M.) Hypertension. 2018 12;72(6):1244-1254 PMID: 30571238 PMCID: PMC6314488 SCOPUS ID: 2-s2.0-85058909343 12/21/2018
(Liu P, Liu Y, Liu H, Pan X, Li Y, Usa K, Mishra MK, Nie J, Liang M.) Hypertension. 2018 11;72(5):1160-1171 PMID: 30354815 PMCID: PMC6314686 SCOPUS ID: 2-s2.0-85055596895 10/26/2018
(Pant T, Dhanasekaran A, Fang J, Bai X, Bosnjak ZJ, Liang M, Ge ZD.) BMC Cardiovasc Disord. 2018 10 20;18(1):197 PMID: 30342478 PMCID: PMC6196023 SCOPUS ID: 2-s2.0-85055075405 10/22/2018